ExploreConditionyouth anxiety disorders
Condition

youth anxiety disorders

Also known as: youth anxiety disorders; internalizing psychopathology AD
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
outcomes
populations
studys

Findings (27)

None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0
None
improvement

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Size: COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Papers (1)